NCT04532021 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Committee on Practice Bulletins-Obstetrics
ACOG Practice Bulletin No. 188: Prelabor Rupture of Membranes. Obstet Gynecol. 2018 Jan;131(1):e1-e14. doi: 10.1097/AOG.0000000000002455. Review.
Ekström B, Berggård I
Human alpha1-microglobulin. Purification procedure, chemical and physiochemical properties. J Biol Chem. 1977 Nov 25;252(22):8048-57.
Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, ten Dijke P
Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res. 2010 May 15;70(10):4141-50. doi: 10.1158/0008-5472.CAN-09
Nergiz Avcioglu S, Demircan Sezer S, Küçük M, Zafer E, Yüksel H, Akcan B, Turgut O
Maternal serum concentrations of s-Endoglin and IL-6 in pregnancy complicated by preterm premature membrane rupture. J Matern Fetal Neonatal Med. 2016;29(12):1957-62. doi:

Umbilical Cord and Maternal Blood Concentrations of Matrix Metalloproteinase 14, Neopterin, and Orosomucoid 1 in Pregnancy Complicated by Preterm Premature Rupture of the Membranes and Histological Chorioamnionitis

Details for clinical trial NCT04532021

Clinical trial NCT04532021 - References